Meeting
2023 ASCO Breakthrough
Efficacy of PD-1 inhibitors in the treatment of advanced gastrointestinal tumors and the effect on T-lymphocyte subsets and IL-6 levels in patients.
Authors
XinCheng He
Shaanxi Provincial People’s Hospital, Xi’an, China
XinCheng He , Lei Hou , Jun Bai , Chao Sun , Dongjie Wang , Jinyao He , Li He , Gaili An
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Gastrointestinal Cancer,Gynecologic Cancer,Head and Neck Cancer,Quality of Care,Genetics/Genomics/Multiomics,Healthcare Equity and Access to Care,Healthtech Innovations,Models of Care and Care Delivery,Population Health,Viral-Mediated Malignancies
Sub Track
Immunotherapies
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 44)
DOI
10.1200/GO.2023.9.Supplement_1.44
Abstract #
44
Poster Bd #
C1
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Update on safety and efficacy of a phase 1/2 of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).
First Author: Alain Patrick Algazi
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2019 ASCO Annual Meeting
A multicenter, phase II study of soluble LAG-3 (Eftilagimod Alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).
First Author: Julio Antonio Peguero
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.
First Author: Laurent Mhanna